Distinguished in Cervical Dysplasia

Dr. Monica P. Hayes

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Icahn School Of Medicine At Mount Sinai
1 Gustave Levy Place, 
New York, NY 
Offers Telehealth
Distinguished in Cervical Dysplasia
Icahn School Of Medicine At Mount Sinai
1 Gustave Levy Place, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Monica Hayes is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Hayes and is rated as a Distinguished provider by MediFind in the treatment of Cervical Dysplasia. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Cervical Dysplasia.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
Mount Sinai Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
1 Gustave Levy Place, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tisotumab vedotin
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

4 Total Publications

Primary Anal Cancer Screening Results From 381 Women With Human Immunodeficiency Virus.
Primary Anal Cancer Screening Results From 381 Women With Human Immunodeficiency Virus.
Journal: The Journal of infectious diseases
Published: June 13, 2022
Similar Doctors
Elite in Cervical Dysplasia
Dr. Mark H. Einstein
Obstetrics and Gynecology | Gynecologic Oncology | Oncology
Elite in Cervical Dysplasia
Dr. Mark H. Einstein
Obstetrics and Gynecology | Gynecologic Oncology | Oncology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (7.3 mi)
Languages Spoken:
English
Accepting New Patients

Mark Einstein is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Bronx, New York. Dr. Einstein and is rated as a Distinguished provider by MediFind in the treatment of Cervical Dysplasia. His top areas of expertise are Cervical Dysplasia, Cervical Cancer, Human Papillomavirus Infection, Hysterectomy, and Endoscopy. Dr. Einstein is currently accepting new patients.

Distinguished in Cervical Dysplasia
Dr. Kevin M. Holcomb
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Cervical Dysplasia
Dr. Kevin M. Holcomb
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

North Shore-Lij Medical PC

27005 76th Ave Gf, 
New Hyde Park, NY 
 (14.6 mi)
718-470-7501
Languages Spoken:
English

Kevin Holcomb is a Gynecologic Oncologist and an Oncologist in New Hyde Park, New York. Dr. Holcomb and is rated as a Distinguished provider by MediFind in the treatment of Cervical Dysplasia. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Dysplasia, Salpingo-Oophorectomy, and Oophorectomy.

Distinguished in Cervical Dysplasia
Dr. Thomas E. Hackett
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Cervical Dysplasia
Dr. Thomas E. Hackett
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Barnabas Health Medical Group PC

94 Old Short Hills Rd, 
Livingston, NJ 
 (18.5 mi)
Languages Spoken:
English
See accepted insurances

Thomas Hackett is a Gynecologic Oncologist and an Oncologist in Livingston, New Jersey. Dr. Hackett and is rated as a Distinguished provider by MediFind in the treatment of Cervical Dysplasia. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Oophorectomy, and Salpingo-Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hayes's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile